Table 3

Comparison of the characteristics of diagnosed and undiagnosed clinically significant COPD in England

UndiagnosedDiagnosed
Number of participants840131
Age (years)
 30–3913 (1.6%)0
 40–4970 (8.3%)8 (6.1%)
 50–59137 (16.3%)19 (14.5%)
 60–69257 (30.6%)41 (31.3%)
 70–79266 (31.7%)53 (40.5%)
 ≥8097 (11.6%)10 (7.6%)
(p=0.2)
Sex
 Male490 (58.3%)84 (64.1%)
 Female350 (41.7%)47 (35.9%) (p=0.2)
Smoking status
 Current370 (44.1%)53 (40.5%)
 Ex-regular328 (39.1%)69 (52.7%)
 Never regular141 (16.8%)9 (6.9%) (p=0.002)
Reported respiratory symptoms
 Dyspnoea651 (77.5%)110 (84.0%) (p=0.09)
  MRC grade 3 or worse323 (38.5%)91 (69.5%) (p<0.001)
 Wheeze548 (65.2%)119 (90.8%) (p<0.001)
 Chronic cough366 (43.6%)93 (71.0%) (p<0.001)
 Chronic phlegm305 (36.3%)89 (67.9%) (p<0.001)
 Frequent winter bronchitis428 (51.0%)105 (80.2%) (p<0.001)
 Any of the above respiratory symptoms840 (100%)131 (100%)
Severity of airflow obstruction*
Stage (FEV1% predicted)
 II (50–80%)628 (74.8%)55 (42.0%)
 III (30–49%)181 (21.6%)52 (39.7%)
 IV (<30%)31 (3.7%)24 (18.3%) (p<0.001)
Likely to benefit most from disease-modifying treatment (FEV1 <50% predicted or MRC grade 3 dyspnoea)417 (49.6%)104 (79.4%) (p<0.001)
  • * Stage according to GOLD (Global Initiative for Chronic Obstructive Lung Disease) guidelines.

  • COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; MRC, Medical Research Council.